Advertisement

Topics

Protalix Biotherapeutics, Inc. Company Profile

09:33 EDT 22nd September 2017 | BioPortfolio

Protalix is a biopharmaceutical company focused on the development and commercialization of proprietary recombinant therapeutic proteins expressed through its proprietary plant cell based expression system. Protalix’s ProCellEx(TM) presents a proprietary method for the expression of recombinant proteins that Protalix believes will allow for the cost-effective, industrial-scale production of recombinant therapeutic proteins in an environment free of mammalian components and viruses. Protalix is also advancing additional recombinant biopharmaceutical drug development programs. Taliglucerase alfa is an enzyme replacement therapy in development under a Special Protocol Assessment with FDA for Gaucher’s disease.


News Articles [189 Associated News Articles listed on BioPortfolio]

Protalix sells $10mm in convertible notes

Protalix BioTherapeutics Inc. (protein therapies for metabolic conditions) raised $10mm through the private placement of 7.50% senior secured convertible notes due 2021. The initial conversion rate wi...

Protalix BioTherapeutics: A Novel Enzymes Innovator For Orphan Diseases

Protalix BioTherapeutics Reports 2017 First Quarter Results and Provides Corporate Update

Positive Results from Phase II Trial in CF Program with Number of Potential Strategic Alternatives for Further Development First Ever Once Monthly Dosing Trial in Fabry Patients to Commence Next ...

Protalix BioTherapeutics to Present at the Jefferies 2017 Global Healthcare Conference

CARMIEL, Israel, May 25, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recomb...

Protalix BioTherapeutics' (PLX) CEO Moshe Manor on Q2 2017 Results - Earnings Call Transcript

Protalix BioTherapeutics' (PLX) CEO Moshe Manor on Q1 2017 Results - Earnings Call Transcript

Protalix Biotherapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

CARMIEL, Israel, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization o...

Protalix Biotherapeutics, Inc. Reports 2017 Second Quarter Results and Provides Corporate Update

  Life Sciences Jobs   ...

Drugs and Medications [14 Associated Drugs and Medications listed on BioPortfolio]

Plasmanate [TALECRIS BIOTHERAPEUTICS, INC.]

Plasma Protein Fraction (Human) 5%, USPPlasmanate®

Gamastan s/d [TALECRIS BIOTHERAPEUTICS, INC.]

Immune Globulin (Human)GamaSTAN™ S/DSolvent/Detergent Treated

Plasbumin [TALECRIS BIOTHERAPEUTICS, INC.]

Albumin (Human) 5%, USPPlasbumin ®-5

Plasbumin [TALECRIS BIOTHERAPEUTICS, INC.]

Albumin (Human) 5%, USPPlasbumin ®-5

Plasbumin [TALECRIS BIOTHERAPEUTICS, INC.]

Albumin (Human) 20%, USPPlasbumin®-20

PubMed Articles [14 Associated PubMed Articles listed on BioPortfolio]

Using transgenic plants and modified plant viruses for the development of treatments for human diseases.

Production of proteins in plants for human health applications has become an attractive strategy attributed by their potentials for low-cost production, increased safety due to the lack of human or an...

TILT Biotherapeutics.

Peptide dendrons as thermal stability amplifiers for IgG1 monoclonal antibody biotherapeutics.

Biotherapeutics such as monoclonal antibodies (mAbs) have a major share of the pharmaceutical industry for treatment of life-threatening chronic diseases such as cancer, skin ailments and immune disor...

Recommendations for Systematic Statistical Computation of Immunogenicity Cut Points.

Today, the assessment of immunogenicity is integral in nonclinical and clinical testing of new biotherapeutics and biosimilars. A key component in the risk-based evaluation of immunogenicity involves ...

To engraft or not to engraft: an ecological framework for gut microbiome modulation with live microbes.

Strategies aimed at modulating the gut microbiota by using live microbes range from single strains (probiotics or live biotherapeutics) to whole non-defined fecal transplants. Although often clinicall...

Clinical Trials [4 Associated Clinical Trials listed on BioPortfolio]

Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)

The purpose of this study is to: - evaluate the safety profile of a single intravenous administration of AIGIV (containing either 3.5 mg/kg, 7.0 mg/kg or 14.0 mg/kg anti-PA IgG) a...

A Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Injections of Elamipretide (MTP-131) in Subjects With Genetically Confirmed Mitochondrial Disease Previously Treated in the Stealth BioTherapeutics SPIMM-201 Study

This is a Phase 2, randomized, double-blind, placebo-controlled crossover study which will enroll up to 36 subjects (anticipated) with genetically confirmed mitochondrial disease who have ...

The Effect of OASIS Ultra on Critical Sized Wound Healing

The aim of this study is to evaluate the speed and quality with which OASIS® Ultra (Healthpoint Biotherapeutics; Fort Worth, Texas) increases wound healing in the critical sized defect. ...

Personalized Immunotherapeutics for Antibiotic-resistant Infection

M. A. suffers from hypogammaglobulinemia that has been complicated by refractory Mycoplasma hominis septic arthritis. He has been receiving the antibiotic valnemulin under Emergency Invest...

Companies [93 Associated Companies listed on BioPortfolio]

Protalix Biotherapeutics, Inc.

Protalix is a biopharmaceutical company focused on the development and commercialization of proprietary recombinant therapeutic proteins expressed through its proprietary plant ce...

Axial Biotherapeutics

Axial Biotherapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and the central nervous system to develop a new class of biotherapeutics ...

Napro Biotherapeutics Incorporated

NaPro BioTherapeutics, Inc. is a natural product pharmaceutical company focused primarily on the development, manufacture and commercializa tion of paclitaxel, a naturally-occurring anti-cancer agent ...

Sephos Biotherapeutics

Sephos Biotherapeutics is a privately owned company focused on designing drugs for the treatment of cancer stem cells where the structure and biological activity of the drugs have...

Talecris Biotherapeutics Holdings Inc.

Talecris Biotherapeutics (Nasdaq: TLCR) is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders i...

More Information about "Protalix Biotherapeutics, Inc." on BioPortfolio

We have published hundreds of Protalix Biotherapeutics, Inc. news stories on BioPortfolio along with dozens of Protalix Biotherapeutics, Inc. Clinical Trials and PubMed Articles about Protalix Biotherapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Protalix Biotherapeutics, Inc. Companies in our database. You can also find out about relevant Protalix Biotherapeutics, Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record